Migraines can significantly reduce the quality of life of those affected. Early treatment is therefore advisable if the diagnosis is confirmed. Migraine therapy can be divided into three groups: Acute therapy, prophylaxis, non-drug measures. Monoclonal antibodies against CGRP and the CGRP receptor are now well established for long-term drug prophylaxis. The new up-and-coming generation of migraine drugs includes Ditane and Gepante.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- IBDmatters - Synergy effects for IBD pathways
How combination therapies lead to better treatment results
- Important basics and studies on cancer and the psyche